These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
4. Noninvasive imaging and radiovirotherapy of prostate cancer using an oncolytic measles virus expressing the sodium iodide symporter. Msaouel P; Iankov ID; Allen C; Aderca I; Federspiel MJ; Tindall DJ; Morris JC; Koutsilieris M; Russell SJ; Galanis E Mol Ther; 2009 Dec; 17(12):2041-8. PubMed ID: 19773744 [TBL] [Abstract][Full Text] [Related]
5. Tumor and vascular targeting of a novel oncolytic measles virus retargeted against the urokinase receptor. Jing Y; Tong C; Zhang J; Nakamura T; Iankov I; Russell SJ; Merchan JR Cancer Res; 2009 Feb; 69(4):1459-68. PubMed ID: 19208845 [TBL] [Abstract][Full Text] [Related]
6. Interleukin-13 displaying retargeted oncolytic measles virus strains have significant activity against gliomas with improved specificity. Allen C; Paraskevakou G; Iankov I; Giannini C; Schroeder M; Sarkaria J; Schroeder M; Puri RK; Russell SJ; Galanis E Mol Ther; 2008 Sep; 16(9):1556-64. PubMed ID: 18665158 [TBL] [Abstract][Full Text] [Related]
7. Oncolytic measles virus retargeting by ligand display. Msaouel P; Iankov ID; Allen C; Russell SJ; Galanis E Methods Mol Biol; 2012; 797():141-62. PubMed ID: 21948475 [TBL] [Abstract][Full Text] [Related]
8. Use of a vaccine strain of measles virus genetically engineered to produce carcinoembryonic antigen as a novel therapeutic agent against glioblastoma multiforme. Phuong LK; Allen C; Peng KW; Giannini C; Greiner S; TenEyck CJ; Mishra PK; Macura SI; Russell SJ; Galanis EC Cancer Res; 2003 May; 63(10):2462-9. PubMed ID: 12750267 [TBL] [Abstract][Full Text] [Related]
9. A measles virus vaccine strain derivative as a novel oncolytic agent against breast cancer. McDonald CJ; Erlichman C; Ingle JN; Rosales GA; Allen C; Greiner SM; Harvey ME; Zollman PJ; Russell SJ; Galanis E Breast Cancer Res Treat; 2006 Sep; 99(2):177-84. PubMed ID: 16642271 [TBL] [Abstract][Full Text] [Related]
10. Prostate-specific antigen-retargeted recombinant newcastle disease virus for prostate cancer virotherapy. Shobana R; Samal SK; Elankumaran S J Virol; 2013 Apr; 87(7):3792-800. PubMed ID: 23345509 [TBL] [Abstract][Full Text] [Related]
11. Retargeted and Stealth-Modified Oncolytic Measles Viruses for Systemic Cancer Therapy in Measles Immune Patients. Bah ES; Nace RA; Peng KW; Muñoz-Alía MÁ; Russell SJ Mol Cancer Ther; 2020 Oct; 19(10):2057-2067. PubMed ID: 32847970 [TBL] [Abstract][Full Text] [Related]
12. PSMA specific single chain antibody-mediated targeted knockdown of Notch1 inhibits human prostate cancer cell proliferation and tumor growth. Su Y; Yu L; Liu N; Guo Z; Wang G; Zheng J; Wei M; Wang H; Yang AG; Qin W; Wen W Cancer Lett; 2013 Sep; 338(2):282-91. PubMed ID: 23752065 [TBL] [Abstract][Full Text] [Related]
13. A recombinant measles virus vaccine strain rMV-Hu191 has oncolytic effect against human gastric cancer by inducing apoptotic cell death requiring integrity of lipid raft microdomains. Lv Y; Zhou D; Hao XQ; Zhu MY; Zhang CD; Zhou DM; Wang JH; Liu RX; Wang YL; Gu WZ; Shen HQ; Chen X; Zhao ZY Cancer Lett; 2019 Sep; 460():108-118. PubMed ID: 31226409 [TBL] [Abstract][Full Text] [Related]
14. Measles virus induces oncolysis of mesothelioma cells and allows dendritic cells to cross-prime tumor-specific CD8 response. Gauvrit A; Brandler S; Sapede-Peroz C; Boisgerault N; Tangy F; Gregoire M Cancer Res; 2008 Jun; 68(12):4882-92. PubMed ID: 18559536 [TBL] [Abstract][Full Text] [Related]
15. Antitumor Activity of MEDI3726 (ADCT-401), a Pyrrolobenzodiazepine Antibody-Drug Conjugate Targeting PSMA, in Preclinical Models of Prostate Cancer. Cho S; Zammarchi F; Williams DG; Havenith CEG; Monks NR; Tyrer P; D'Hooge F; Fleming R; Vashisht K; Dimasi N; Bertelli F; Corbett S; Adams L; Reinert HW; Dissanayake S; Britten CE; King W; Dacosta K; Tammali R; Schifferli K; Strout P; Korade M; Masson Hinrichs MJ; Chivers S; Corey E; Liu H; Kim S; Bander NH; Howard PW; Hartley JA; Coats S; Tice DA; Herbst R; van Berkel PH Mol Cancer Ther; 2018 Oct; 17(10):2176-2186. PubMed ID: 30065100 [TBL] [Abstract][Full Text] [Related]
16. Inhibition of Rho-associated coiled-coil-forming kinase increases efficacy of measles virotherapy. Opyrchal M; Allen C; Msaouel P; Iankov I; Galanis E Cancer Gene Ther; 2013 Nov; 20(11):630-7. PubMed ID: 24157925 [TBL] [Abstract][Full Text] [Related]
17. Armed and targeted measles virus for chemovirotherapy of pancreatic cancer. Bossow S; Grossardt C; Temme A; Leber MF; Sawall S; Rieber EP; Cattaneo R; von Kalle C; Ungerechts G Cancer Gene Ther; 2011 Aug; 18(8):598-608. PubMed ID: 21701532 [TBL] [Abstract][Full Text] [Related]
18. Recombinant measles virus induces cytolysis of cutaneous T-cell lymphoma in vitro and in vivo. Künzi V; Oberholzer PA; Heinzerling L; Dummer R; Naim HY J Invest Dermatol; 2006 Nov; 126(11):2525-32. PubMed ID: 16960554 [TBL] [Abstract][Full Text] [Related]
19. Measles virus selectively blind to signaling lymphocyte activation molecule as a novel oncolytic virus for breast cancer treatment. Sugiyama T; Yoneda M; Kuraishi T; Hattori S; Inoue Y; Sato H; Kai C Gene Ther; 2013 Mar; 20(3):338-47. PubMed ID: 22717740 [TBL] [Abstract][Full Text] [Related]
20. Epidermal growth factor receptor (EGFR)-retargeted measles virus strains effectively target EGFR- or EGFRvIII expressing gliomas. Paraskevakou G; Allen C; Nakamura T; Zollman P; James CD; Peng KW; Schroeder M; Russell SJ; Galanis E Mol Ther; 2007 Apr; 15(4):677-86. PubMed ID: 17299404 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]